SVF
Level B· Emerging Clinical EvidenceRandomized Controlled Trial

Efficacy of allogeneic mesenchymal stem cell administration in a model of acute ischemic kidney injury in cats.

Rosselli DD., Mumaw JL., Dickerson V., Brown CA., Brown SA., Schmiedt CW.

Randomized Controlled Trial with a reported sample of 15 on Acute Kidney Injury, published in Res Vet Sci (2016) — summary generated from the PubMed abstract.

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Randomized Controlled Trial
Journal
Res Vet Sci (2016)
Country
England
Reported sample size
15
PMID
27663365
DOI
10.1016/j.rvsc.2016.07.003

Abstract (original English)

To evaluate the effects of allogeneic mesenchymal stem cells (MSCs) in a model of ischemic acute kidney injury (AKI). Randomized controlled trial. Adult, purpose-bred research cats (n=15) and a historical reference group (n=3). Cats underwent unilateral, in vivo, warm renal ischemia, then intravenous administration of 4 million adipose-derived MSCs, bone marrow-derived MSCs, or fibroblasts (n=5/treatment) 1h after reperfusion. Serum creatinine and blood urea nitrogen concentrations were measured at baseline and days 1 and 6. Urine specific gravity, urine protein to urine creatinine ratio, and glomerular filtration rate were measured at baseline and day 6. Both kidneys were harvested on day 6; histopathology was described and scored and smooth muscle actin was quantified with histomorphometry. A 2-way ANOVA was used to compare time and treatment. Chi square analysis was used to determine the % of cats with at least International Renal Interest Society (IRIS) Grade 1 AKI. Time, but not treatment, had a significant effect on renal function. No difference was noted in % of cats with IRIS AKI. Significantly fewer mitotic figures were observed in ischemic kidneys that received bone-marrow derived MSCs vs. fibroblasts. No differences in smooth muscle actin staining were noted. This study did not support the use of allogeneic MSCs in AKI in the regimen described here. Type of renal inj

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.

Evidence level

Several human studies exist, but sample sizes, methodology, or follow-up remain limited, so conclusions are not firm.

How we grade evidence
Acute Kidney InjuryAdipose TissueAdministration, IntravenousAnimalsBone Marrow CellsCatsDisease Models, AnimalFemaleHumansMale
Systemic / IVAcute Kidney Injury
View on PubMedDOI

Related research